A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Have been diagnosed with obesity OR overweight with at least 1 weight-related comorbidity (abnormal lipids, high blood pressure, fatty liver disease, sleep apnea, prediabetes or type 2 diabetes)
Have not been able to lose weight with healthy diet and physical activity
If with Type 2 diabetes mellitus have been treated with either diet and exercise alone or with metformin for at least 90 days prior to screening and have a HbA1c <9.0%
Have started puberty
Participants Must Not:
Have lost more than 5 kg (11 lbs) in the 90 days before screening
Have Type 1 Diabetes
Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome Type 2
Have a history of pancreatitis
Have had or plan to have a weight loss surgery during the study
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo